A law that coaxed companies to lower the price of drugs came with a little-known consequence: smaller discounts for ...

While this option may be less expensive and seems convenient, it’s best to consult a doctor about dosage if you use it, says Joshua J. Neumiller, CDCES, PharmD, the president elect of ...

With an increased confidence in the company’s prospects, HSBC raised its earnings estimates for Biocon, projecting ...

After the clearance from US drugs regulator, Motilal Oswal has upgraded Biocon to 'buy' with a target price of Rs 430 apiece.

Let’s not demonize carbohydrates and insulin. Carbohydrates are beneficial for fueling the body for exercise and demanding ...

In a report released today, Joanne Wuensch from Citi reiterated a Buy rating on Insulet (PODD – Research Report). The company’s shares closed ...

The non-profit drugmaker plans to launch biosimilars of Sanofi’s Lantus (insulin glargine), Novo Nordisk’s Novolog (insulin aspart) and Eli Lilly’s Humalog (insulin lispro) by 2024.

H.C. Wainwright analyst Joseph Pantginis has maintained their bullish stance on BMEA stock, giving a Buy rating yesterday.Stay Ahead of the ...

Stocks tend to perform well in January, but that's not a good reason to invest this month. Strong returns aren't made in a ...

Non-profit drugmaker Civica Rx has said it will launch biosimilars of three big-selling insulin products in the US by 2024 to help diabetic patients struggling with the cost of the drugs.

Shares of Insulet Co. (NASDAQ:PODD – Get Free Report) have received a consensus rating of “Moderate Buy” from the sixteen analysts that are currently covering the firm, MarketBeat Ratings reports.

Beyond the glaciers and polar bears, it’s about “unlimited” untapped resources—something Trump likely equates to a hidden ...